Global Blood Therapeutics, Inc. (NASDAQ:GBT) insider Jung Choi sold 3,000 shares of the stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $30.00, for a total transaction of $90,000.00. Following the sale, the insider now directly owns 141,655 shares in the company, valued at approximately $4,249,650. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jung Choi also recently made the following trade(s):

  • On Friday, July 21st, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $90,000.00.

Shares of Global Blood Therapeutics, Inc. (NASDAQ GBT) opened at 28.40 on Thursday. Global Blood Therapeutics, Inc. has a one year low of $13.35 and a one year high of $41.15. The firm’s market cap is $1.24 billion. The company has a 50-day moving average of $28.04 and a 200 day moving average of $30.06.

Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.06. During the same period last year, the business earned ($0.58) earnings per share. On average, equities research analysts expect that Global Blood Therapeutics, Inc. will post ($2.45) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Jung Choi Sells 3,000 Shares of Global Blood Therapeutics, Inc. (GBT) Stock” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/07/jung-choi-sells-3000-shares-of-global-blood-therapeutics-inc-gbt-stock.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley raised its position in shares of Global Blood Therapeutics by 140.0% in the 1st quarter. Morgan Stanley now owns 334,872 shares of the company’s stock valued at $12,340,000 after purchasing an additional 195,323 shares in the last quarter. Creative Planning raised its position in shares of Global Blood Therapeutics by 3,380.5% in the 2nd quarter. Creative Planning now owns 41,801 shares of the company’s stock valued at $1,143,000 after purchasing an additional 40,600 shares in the last quarter. MARSHALL WACE ASIA Ltd acquired a new position in shares of Global Blood Therapeutics in the 1st quarter valued at approximately $694,000. Vanguard Group Inc. raised its position in shares of Global Blood Therapeutics by 40.1% in the 1st quarter. Vanguard Group Inc. now owns 2,535,980 shares of the company’s stock valued at $93,451,000 after purchasing an additional 726,366 shares in the last quarter. Finally, Teachers Advisors LLC raised its position in shares of Global Blood Therapeutics by 426.2% in the 1st quarter. Teachers Advisors LLC now owns 156,195 shares of the company’s stock valued at $5,756,000 after purchasing an additional 126,513 shares in the last quarter. 86.07% of the stock is currently owned by institutional investors.

Several analysts have recently issued reports on GBT shares. Morgan Stanley reissued an “overweight” rating on shares of Global Blood Therapeutics in a research report on Tuesday, July 11th. ValuEngine cut shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 3rd. J P Morgan Chase & Co reissued an “overweight” rating and set a $46.00 price target (up previously from $44.00) on shares of Global Blood Therapeutics in a research report on Tuesday, August 8th. BidaskClub raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Finally, Cowen and Company reissued an “outperform” rating and set a $83.00 price target on shares of Global Blood Therapeutics in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $49.73.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.